DataSheet_1_Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction.pdf

Supplementary Tables Supplementary Table 1: Clinical data of the study cohort. Supplementary Table 2: Functional enrichment by trend of soluble proteins for Diagnostic group study. Supplementary Table 3: Summary of significant soluble proteins for each study after classical statistical analysis. Sup...

Descripción completa

Detalles Bibliográficos
Autores: Landeira-Viñuela, Alicia, Arias-Hidalgo, Carlota, Juanes-Velasco, Pablo, Alcoceba, Miguel, Navarro-Bailón, Almudena, Pedreira, C. E., Lécrevisse, Quentin, Díaz-Muñoz, Laura, Sánchez-Santos, José Manuel, Hernández, Ángela-Patricia, García-Vaquero, Marina L., Góngora, Rafael, De Las Rivas, Javier, González, Marcos, Orfao, Alberto, Fuentes, Manuel
Tipo de recurso: conjunto de datos
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/331024
Acceso en línea:http://hdl.handle.net/10261/331024
Access Level:acceso abierto
Palabra clave:Soluble immune checkpoints
Cytokines profiles
Cellular microenvironment
Chronic lymphocytic leukaemia (CLL)
Immune dysfunction
Descripción
Sumario:Supplementary Tables Supplementary Table 1: Clinical data of the study cohort. Supplementary Table 2: Functional enrichment by trend of soluble proteins for Diagnostic group study. Supplementary Table 3: Summary of significant soluble proteins for each study after classical statistical analysis. Supplementary Table 4: Functional enrichment of significant soluble proteins for comparison Monoclonal B-cell lymphocytosis (MBLhi) vs. Chronic Lymphocytic Leukemia (CLL) and CLL in progression (p-CLL) vs. Stable/constant CLL (c-CLL) vs. MBLhi and combinations. Supplementary Table 5: Functional enrichment of significant soluble proteins according to trend for Diagnostic group study. Supplementary Table 6: Protein correlation. Supplementary Table 7: Top 20/30 proteins after random forest analyses. Supplementary Table 8: Summary of significant soluble proteins for each study after linear model. Supplementary Table 9: Functional enrichment by trend of soluble proteins for Diagnostic group and treatment line. Supplementary Table 10: Functional enrichment of significant soluble proteins for all combination combinations between Monoclonal B-cell lymphocytosis (MBLhi), Stable/constant Chronic Lymphocytic Leukemia (c-CLL), CLL in progression previously to 1st line treatment (CLL-PFT) and CLL in progression to time from 1st line treatment (CLL-TFT). Supplementary Table 11: Functional enrichment by trend of soluble proteins for Immunoglobulin Heavy chain Variable (IGHV) gene status study. Supplementary Table 12: Functional enrichment of significant soluble proteins for Immunoglobulin Heavy chain Variable (IGHV) gene status study.

Similares en LA Referencia